灵康药业：9月22日召开董事会会议

Core Viewpoint - Lingkang Pharmaceutical announced the convening of its 2025 second extraordinary general meeting of shareholders, reflecting ongoing corporate governance and strategic planning efforts [1] Company Summary - Lingkang Pharmaceutical's revenue composition for the year 2024 is as follows: 84.62% from pharmaceuticals, 12.19% from pharmaceutical distribution, 2.7% from other businesses, and 0.48% from hospital sales and distribution [1] - As of the report, Lingkang Pharmaceutical has a market capitalization of 4.1 billion yuan [1]